# US 2006/0135590 A1 · Selected fused pyrrolocarbazoles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0135590 A1
- Document ID: US20060135590A1
- Status: Published application
- Kind: A1
- Application number: 11/350,170
- Filed: 2006-02-08
- Published: 2006-06-22
- Earliest claimed: 2000-08-25
- Assignees: Cephalon, Inc.
- Inventors: Diane Gingrich; Robert Hudkins
- Web page: https://patentgrep.com/patent/US20060135590A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.

## Claims

### Claim 1

A method for treating prostate disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein:
R3 is alkyl of 1-8 carbons substituted with —OH or —SR5;
R5 is alkyl of 1-4 carbons.

### Claim 2 (depends on 1)

The method of claim 1 wherein the prostate disorder is prostate cancer or benign prostate hyperplasia.

### Claim 3

A method for treating angiogenic disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein:
R3 is alkyl of 1-8 carbons substituted with —OH or —SR5;
R5 is alkyl of 1-4 carbons.

### Claim 4 (depends on 3)

The method of claim 3 wherein the angiogenic disorder is cancer of solid tumors, ocular disorders, macular degeneration, endometriosis, diabetic retinopathy, psoriasis, or hemangioblastoma.

### Claim 5

A method for treating pathological disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein:
R3is alkyl of 1-8 carbons substituted with —OH or —SR5;
R5 is alkyl of 1-4 carbons.

### Claim 6 (depends on 5)

The method of claim 5 wherein the pathological disorder is neoplasia, rheumatoid arthritis, chronic arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis.

### Claim 7

A method for treating neurodegenerative diseases and disorders, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, chemotherapy induced peripheral neuropathy, AID related peripheral neuropathy or injuries of the brain or spinal chord which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein:
R3 is alkyl of 1-8 carbons substituted with —OH or —SR5;
R5 is alkyl of 1-4 carbons.

### Claim 8

A method for treating multiple myeloma and leukemias which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein:
R3 is alkyl of 1-8 carbons substituted with —OH or —SR5;
R5 is alkyl of 1-4 carbons.

### Claim 9 (depends on 8)

The method of claim 8 wherein the leukemia is acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, or chronic lymphocytic leukemia.

### Claim 10

A method for treating angiogenic disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein R1 and R3 are selected in accordance with the following table:
Cmpd
R1
R3
37
CH2CH2CH2OCOCF3
CH2SCH2CH2CH3
39
CH2CH2CH2OH
CH2S(2-pyrimidyl)

### Claim 11 (depends on 10)

The method of claim 10 wherein the angiogenic disorder is cancer of solid tumors, ocular disorders, macular degeneration, endometriosis, diabetic retinopathy, psoriasis, or hemangioblastoma.

### Claim 12

A method for treating pathological disorders which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein R1 and R3 are selected in accordance with the following table:
Cmpd
R1
R3
37
CH2CH2CH2OCOCF3
CH2SCH2CH2CH3
39
CH2CH2CH2OH
CH2S(2-pyrimidyl)

### Claim 13 (depends on 12)

The method of claim 12 wherein the pathological disorder is neoplasia, rheumatoid arthritis, chronic arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis.

### Claim 14

A method for treating neurodegenerative diseases and disorders, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, AIDS dementia, epilepsy, multiple sclerosis, peripheral neuropathy, chemotherapy induced peripheral neuropathy, AID related peripheral neuropathy or injuries of the brain or spinal chord which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula I:
wherein R1 and R3 are selected in accordance with the following table:
Cmpd
R1
R3
37
CH2CH2CH2OCOCF3
CH2SCH2CH2CH3
39
CH2CH2CH2OH
CH2S(2-pyrimidyl)

### Claim 15

A method for treating multiple myeloma and leukemias which comprise administering to a host in need of such treatment or prevention a therapeutically effective amount of a compound of Formula I:
wherein R1 and R3 are selected in accordance with the following table:
Cmpd
R1
R3
37
CH2CH2CH2OCOCF3
CH2SCH2CH2CH3
39
CH2CH2CH2OH
CH2S(2-pyrimidyl)

### Claim 16 (depends on 15)

The method of claim 15 wherein the leukemia is acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, or chronic lymphocytic leukemia.
